Evommune, Inc. filed a current report on Form 8-K on November 5, 2026, disclosing under Regulation FD that the company issued a press release announcing a live webcast focused on its EVO570 program.

Key Highlights

  • Filing date: November 5, 2026, reported under Item 7.01 Regulation FD Disclosure.
  • Subject of announcement: A live webcast on EVO570, as described in the attached press release dated November 5, 2026.
  • Exchange listing: Common Stock, $0.0001 par value per share, trades on NYSE:EVMN.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
  • Signing officer: Luis Pena, President and Chief Executive Officer, signed the filing on behalf of Evommune, Inc.
  • Exhibit filed: Press Release dated November 5, 2026, attached as Exhibit 99.1 and incorporated by reference.

Evommune Announces EVO570 Webcast Under Regulation FD

According to the filing, Evommune, Inc., a Delaware-incorporated company headquartered at 1891 Page Mill Road, Palo Alto, CA 94304, issued a press release on November 5, 2026, announcing a live webcast covering its EVO570 program. The disclosure was made under Item 7.01 of Form 8-K, which governs Regulation FD disclosures, ensuring that material information shared with certain market participants is made available to the public broadly and simultaneously.

The filing notes that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section." The company further specified that the press release and related presentation shall not be deemed incorporated by reference into any other regulatory filing by the company, whether made before or after the date of this report. EVO570 is identified by name in the filing as the subject of the announced webcast, underscoring the company's focus on this specific program as a point of investor communication. Evommune carries Commission File Number 001-42938 and IRS Employer Identification Number 85-0742575.

What Was Disclosed

Evommune, Inc. filed an 8-K on November 5, 2026, under Regulation FD to disclose a press release announcing a live webcast on EVO570. The press release is attached as Exhibit 99.1. The report was signed by President and CEO Luis Pena.